156 related articles for article (PubMed ID: 16803502)
1. Pemetrexed (Alimta, LY231514) demonstrates clinical activity in chemonaive patients with cervical cancer in a phase II single-agent trial.
Goedhals L; van Wiyk AL; Smith BL; Fourie SJ
Int J Gynecol Cancer; 2006; 16(3):1172-8. PubMed ID: 16803502
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of the multitargeted antifolate LY231514 (ALIMTA, MTA, pemetrexed disodium) in patients with advanced pancreatic cancer.
Miller KD; Picus J; Blanke C; John W; Clark J; Shulman LN; Thornton D; Rowinsky E; Loehrer PJ
Ann Oncol; 2000 Jan; 11(1):101-3. PubMed ID: 10690396
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of pemetrexed (Alimta, LY231514) as second-line chemotherapy in persistent or recurrent carcinoma of the cervix: the CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group.
Lorusso D; Ferrandina G; Pignata S; Ludovisi M; Viganò R; Scalone S; Scollo P; Breda E; Pietragalla A; Scambia G
Ann Oncol; 2010 Jan; 21(1):61-6. PubMed ID: 19605508
[TBL] [Abstract][Full Text] [Related]
4. A phase I study of pemetrexed (ALIMTA) and cyclophosphamide in patients with locally advanced or metastatic breast cancer.
Dittrich C; Petruzelka L; Vodvarka P; Gneist M; Janku F; Kysela T; Melemed A; Latz J; Simms L; Krejcy K
Clin Cancer Res; 2006 Dec; 12(23):7071-8. PubMed ID: 17145830
[TBL] [Abstract][Full Text] [Related]
5. Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck.
Pivot X; Raymond E; Laguerre B; Degardin M; Cals L; Armand JP; Lefebvre JL; Gedouin D; Ripoche V; Kayitalire L; Niyikiza C; Johnson R; Latz J; Schneider M
Br J Cancer; 2001 Sep; 85(5):649-55. PubMed ID: 11531245
[TBL] [Abstract][Full Text] [Related]
6. A phase II evaluation of pemetrexed (Alimta, LY231514, IND #40061) in the treatment of recurrent or persistent endometrial carcinoma: a phase II study of the Gynecologic Oncology.
Miller DS; Blessing JA; Drake RD; Higgins R; McMeekin DS; Puneky LV; Krasner CN
Gynecol Oncol; 2009 Dec; 115(3):443-6. PubMed ID: 19804902
[TBL] [Abstract][Full Text] [Related]
7. A phase II trial of pemetrexed in patients with metastatic renal cancer.
Thödtmann R; Sauter T; Weinknecht S; Weissbach L; Blatter J; Ohnmacht U; Hanauske A
Invest New Drugs; 2003 Aug; 21(3):353-8. PubMed ID: 14578684
[TBL] [Abstract][Full Text] [Related]
8. Open-label, single-arm phase II study of pemetrexed in the treatment of patients with recurrent or metastatic nasopharyngeal carcinoma who have had prior platinum-based chemotherapy.
Zhang Y; Zhao L; Huang P; Wu J; Wang F; Huang Y; Zhang L
Cancer Chemother Pharmacol; 2012 Oct; 70(4):611-5. PubMed ID: 22903536
[TBL] [Abstract][Full Text] [Related]
9. Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group.
Miller DS; Blessing JA; Krasner CN; Mannel RS; Hanjani P; Pearl ML; Waggoner SE; Boardman CH
J Clin Oncol; 2009 Jun; 27(16):2686-91. PubMed ID: 19332726
[TBL] [Abstract][Full Text] [Related]
10. Pemetrexed in gastric cancer: clinical experience and future perspectives.
Celio L; Buzzoni R; Longarini R; Marchianò A; Bajetta E
Semin Oncol; 2002 Dec; 29(6 Suppl 18):63-8. PubMed ID: 12571814
[TBL] [Abstract][Full Text] [Related]
11. Pemetrexed: a multitargeted antifolate.
Rollins KD; Lindley C
Clin Ther; 2005 Sep; 27(9):1343-82. PubMed ID: 16291410
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma.
Scagliotti GV; Shin DM; Kindler HL; Vasconcelles MJ; Keppler U; Manegold C; Burris H; Gatzemeier U; Blatter J; Symanowski JT; Rusthoven JJ
J Clin Oncol; 2003 Apr; 21(8):1556-61. PubMed ID: 12697881
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium.
Sweeney CJ; Roth BJ; Kabbinavar FF; Vaughn DJ; Arning M; Curiel RE; Obasaju CK; Wang Y; Nicol SJ; Kaufman DS
J Clin Oncol; 2006 Jul; 24(21):3451-7. PubMed ID: 16849761
[TBL] [Abstract][Full Text] [Related]
14. A phase II study of pemetrexed disodium (LY231514) in patients with locally recurrent or metastatic breast cancer.
Miles DW; Smith IE; Coleman RE; Calvert AH; Lind MJ
Eur J Cancer; 2001 Jul; 37(11):1366-71. PubMed ID: 11435066
[TBL] [Abstract][Full Text] [Related]
15. Activity of pemetrexed (ALIMTA, multitargeted antifolate, LY231514) in metastatic breast cancer patients previously treated with an anthracycline and a taxane: an interim analysis.
Spielmann M; Martin M; Namer M; duBois A; Unger C; Dodwell DJ
Clin Breast Cancer; 2001 Apr; 2(1):47-51. PubMed ID: 11899382
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group.
Miller DS; Blessing JA; Bodurka DC; Bonebrake AJ; Schorge JO;
Gynecol Oncol; 2008 Jul; 110(1):65-70. PubMed ID: 18455781
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma.
Galsky MD; Mironov S; Iasonos A; Scattergood J; Boyle MG; Bajorin DF
Invest New Drugs; 2007 Jun; 25(3):265-70. PubMed ID: 17146733
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of pemetrexed in patients pretreated with an anthracycline, a taxane, and capecitabine for advanced breast cancer.
O'Shaughnessy JA; Clark RS; Blum JL; Mennel RG; Snyder D; Ye Z; Liepa AM; Melemed AS; Yardley DA
Clin Breast Cancer; 2005 Jun; 6(2):143-9. PubMed ID: 16001992
[TBL] [Abstract][Full Text] [Related]
19. Phase I trials of pemetrexed.
Fossella FV; Gatzemeier U
Semin Oncol; 2002 Apr; 29(2 Suppl 5):8-16. PubMed ID: 12023787
[TBL] [Abstract][Full Text] [Related]
20. FDA drug approval summaries: pemetrexed (Alimta).
Hazarika M; White RM; Johnson JR; Pazdur R
Oncologist; 2004; 9(5):482-8. PubMed ID: 15477632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
